Verified publication
Elamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages.
Verified PubMed record for SS-31: Elamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages.
PubMed metadata verifiedQuality: Not assessedLow confidence
Study metadata
- Journal
- Antioxidants (Basel, Switzerland)
- Publication year
- 2023
- Study type
- In vitro study
- Species
- Cell or artificial model
- Evidence grade
- Grade C
- Extraction depth
- PubMed metadata verified
- Study quality
- Not assessed
- Confidence
- Low confidence
- Sample size
- Not stated in indexed abstract
Structured extraction
- Population
- Cell or artificial model; cell line and assay details require article-level extraction.
- Intervention
- In vitro exposure details require abstract or full-text extraction before use.
- Comparator
- Not extracted from PubMed metadata.
- Duration
- Not extracted from PubMed metadata.
- Primary endpoint
- Primary assay endpoint not fully extracted.
- Secondary endpoints
- No secondary endpoints extracted.
- Funding source
- Not extracted from PubMed metadata.
Findings and extraction notes
- PubMed indexes this publication under PMID 38136142; Atlas verified title, journal, year, and DOI metadata where available before publishing the page.
- The record is linked to SS-31 for literature mapping, but Atlas has not promoted the indexed metadata into a mechanistic or clinical outcome claim.
Limitations
- Phase 3 metadata verification confirms citation identity; it does not replace full independent extraction of methods, endpoints, or effect sizes.
- Interpretation should remain limited to the publication type, species context, and verified PubMed metadata shown on this page.